Pacific Edge refreshes board of directors

Cancer diagnostic specialist, Pacific Edge, is looking to add further commercial and international expertise to its Board as it builds its sales and marketing platform in the United States and looks to expand its footprint in other markets.

The Pacific Edge Board has been progressing a review of the skills and capabilities required to provide the most appropriate governance as the Company builds on its commercial platform.

Over the last 12 months, Bryan Williams, who recently held the position of chairman of a NASDAQ listed therapeutic development company, has been appointed as an independent Director to the Pacific Edge Board. In addition, Bruce Nogales, who has significant skills and capabilities in medical technology commercialisation in the US, joined the board of the Company's US subsidiary, Pacific Edge Diagnostics USA Limited in 2013.

A further step in the Board refresh process has been triggered following the recent resignation of Colin Dawson who has helped guide the Company through its formative and early stages of growth. Colin's resignation will take effect at the close of the annual shareholders meeting to be held in Dunedin on 21 August 2014.

Chairman Chris Swann, said: "On behalf of the Board, I would like to thank Colin for the significant contribution he has made in bringing the Company to the point where it is today with its first cancer diagnostic system, Cxbladder, acclaimed by clinicians in the United States and other markets as leading technology in the accurate diagnosis of bladder cancer."

"Pacific Edge is now successfully commercialising the Cxbladder technology in the world's largest health market, the US, and looking to further developments of the Cxbladder system. In line with this, the Board has identified a number of commercialisation skills and capabilities that would be of value to the Company. We are in discussions with several candidates and we hope to make an announcement on appointment of new directors in the near future."

At the annual meeting shareholders will be invited to re-elect Chris Swann and David Band as Directors. Shareholders will also be asked to support the election of Chief Executive Officer David Darling as an Executive Director.

Future appointments are likely to increase the size of the Board from six to eight members. The Company is seeking shareholder approval at the annual meeting to increase the maximum pool of fees for non-executive directors by $26,000 to $198,000.

The annual meeting is scheduled to begin at 4pm on 21 August 2014 and will be held at the Dunedin Public Art Gallery.